Christophe Lèguevaques, a lawyer since 1992, discovered 'class actions' at the AZF factory explosion in Toulouse in 2001.

He realised that French law was not suitable for handling mass claims and a large number of claimants.

He then studied the American class action system and the intermediate solution between common law and continental law proposed by Canadian law and its 'class action'. 

When France finally adopted a 'class action' mechanism in 2014, he was one of the first to denounce the illusion of this procedure. 

He also created a platform (MySmartCab) designed to connect potential clients and lawyers. Through this platform, he successfully demonstrated the flexibility and effectiveness of 'joint collective action', as on 16 March 2022, the French Supreme Court ordered MERCK Laboratories to compensate 3,300 victims of the LEVOTHYROX wording change. 

In the wake of this success, it created a second, more sophisticated platform (www.myleo.legal) with the ambition to offer its services on a B2B basis in France and throughout the EU. MyLeo is involved in class actions in the fields of medical law (Philips respirators), financial law (bankruptcy of the Swoon bank), environmental law (chlordecone), consumer law (TCE engines, Puretech engines, Takata airbags, etc.) and labour law. 

On 16 March 2022, in the Levothyrox case, the French Court of Cassation confirmed the decision of the Lyon Court of Appeal of 25 June 2020, which had condemned the Merck company for 'moral prejudice' in a class action brought by Christophe Lèguevaques. In this sense, together with his team, Christophe Lèguevaques is a benchmark in class action law in France.